Exploiting leucine metabolism for therapeutic benefit in acute Myeloid Leukemia
1 Biomedical Science (Clinical Biochemistry) Health and Life Sciences, University of the West of England, Bristol, UK
2 Department of GI Science and Geo-environment, Western Illinois University, Macomb, 61455, USA.
3 Young’s Organization of Urban Research (YOUR), Mirpur, Dhaka 1216, Bangladesh.
Research Article
GSC Advanced Research and Reviews, 2024, 19(01), 053–068.
Article DOI: 10.30574/gscarr.2024.19.1.0135
Publication history:
Received on 28 February 2024; revised on 07 April 2024; accepted on 09 April 2024
Abstract:
Acute Myeloid Leukemia (AML) presents significant challenges in treatment, especially for elderly patients. Conventional therapies have limitations, necessitating the exploration of novel strategies. Metabolic reprogramming in cancer cells offers promise in this regard, with growing evidence pointing to dysregulated leucine metabolism in AML. Leucine deprivation has shown potential in inhibiting leukemic cell proliferation, inducing cell cycle arrest, and enhancing differentiation. Combination therapies involving leucine deprivation and chemotherapy have exhibited synergistic effects. The precise molecular mechanisms of leucine deprivation's anti-leukemic effects, particularly its potential impact on the mTOR signaling pathway, require further elucidation. Targeting BCAAs and other amino acids, such as methionine and lysine, holds promise in disrupting leukemia cell proliferation and promoting apoptosis. These findings underscore the potential of exploiting leucine metabolism and amino acid pathways for therapeutic benefits in AML.
Keywords:
Acute Myeloid Leukemia (AML); Leucine deprivation; Branched-chain amino acids (BCAAs); Therapeutic benefits in AML
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
